000283152 001__ 283152
000283152 005__ 20240229162401.0
000283152 0247_ $$2doi$$a10.2967/jnumed.123.265751
000283152 0247_ $$2pmid$$apmid:37734836
000283152 0247_ $$2ISSN$$a0097-9058
000283152 0247_ $$2ISSN$$a0022-3123
000283152 0247_ $$2ISSN$$a0161-5505
000283152 0247_ $$2ISSN$$a1535-5667
000283152 0247_ $$2ISSN$$a2159-662X
000283152 0247_ $$2altmetric$$aaltmetric:154645803
000283152 037__ $$aDKFZ-2023-01938
000283152 041__ $$aEnglish
000283152 082__ $$a610
000283152 1001_ $$0P:(DE-HGF)0$$aDemmert, Tristan T$$b0
000283152 245__ $$aOncologic Staging with 68Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than 18F-FDG PET/CT.
000283152 260__ $$aNew York, NY$$bSoc.$$c2023
000283152 3367_ $$2DRIVER$$aarticle
000283152 3367_ $$2DataCite$$aOutput Types/Journal article
000283152 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1702549210_27018
000283152 3367_ $$2BibTeX$$aARTICLE
000283152 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283152 3367_ $$00$$2EndNote$$aJournal Article
000283152 500__ $$a2023 Dec 1;64(12):1906-1909
000283152 520__ $$aNonspecific lymph node uptake on 18F-FDG PET/CT imaging is a significant pitfall for tumor staging. Fibroblast activation protein α expression on cancer-associated fibroblasts and some tumor cells is less sensitive to acute inflammatory stimuli, and fibroblast activation protein-directed PET may overcome this limitation. Methods: Eighteen patients from our prospective observational study underwent 18F-FDG and 68Ga fibroblast activation protein inhibitor (FAPI) PET/CT scans within a median of 2 d (range, 0-22 d). Lymph nodes were assessed on histopathology and compared with SUV measurements. Results: On a per-patient basis, lymph nodes were rated malignant in 10 (56%) versus 7 (39%) patients by 18F-FDG PET/CT versus 68Ga-FAPI PET/CT scans, respectively, with a respective accuracy of 55% versus 94% for true lymph node metastases. Five of 6 (83%) false-positive nodes on the 18F-FDG PET/CT scans were rated true negative by the 68Ga-FAPI PET/CT scans. On a per-lesion basis, tumor detection rates were similar (85/89 lesions, 96%). Conclusion: 68Ga-FAPI PET/CT imaging demonstrated higher accuracy for true nodal involvement and therefore has the potential to replace 18F-FDG PET/CT imaging for cancer staging.
000283152 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000283152 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000283152 650_7 $$2Other$$a18F-FDG PET/CT
000283152 650_7 $$2Other$$a68Ga-FAPI PET/CT
000283152 650_7 $$2Other$$alymph node staging
000283152 650_7 $$2Other$$aoncologic staging
000283152 7001_ $$aPomykala, Kelsey L$$b1
000283152 7001_ $$0P:(DE-HGF)0$$aLanzafame, Helena$$b2
000283152 7001_ $$0P:(DE-HGF)0$$aPabst, Kim M$$b3
000283152 7001_ $$0P:(DE-HGF)0$$aLueckerath, Katharina$$b4
000283152 7001_ $$0P:(DE-He78)026e0a55b968f360a3c349689ce8a99c$$aSiveke, Jens$$b5$$udkfz
000283152 7001_ $$aUmutlu, Lale$$b6
000283152 7001_ $$0P:(DE-HGF)0$$aHautzel, Hubertus$$b7
000283152 7001_ $$0P:(DE-HGF)0$$aHamacher, Rainer$$b8
000283152 7001_ $$0P:(DE-HGF)0$$aHerrmann, Ken$$b9
000283152 7001_ $$0P:(DE-HGF)0$$aFendler, Wolfgang P$$b10
000283152 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.123.265751$$gp. jnumed.123.265751 -$$n12$$p1906-1909$$tJournal of nuclear medicine$$v64$$x0097-9058$$y2023
000283152 909CO $$ooai:inrepo02.dkfz.de:283152$$pVDB
000283152 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000283152 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000283152 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000283152 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000283152 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)026e0a55b968f360a3c349689ce8a99c$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000283152 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000283152 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000283152 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000283152 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000283152 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000283152 9141_ $$y2023
000283152 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-19
000283152 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-19
000283152 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-19
000283152 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2022$$d2023-10-24
000283152 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000283152 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000283152 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000283152 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000283152 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-24
000283152 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000283152 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-24
000283152 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000283152 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2022$$d2023-10-24
000283152 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000283152 980__ $$ajournal
000283152 980__ $$aVDB
000283152 980__ $$aI:(DE-He78)ED01-20160331
000283152 980__ $$aUNRESTRICTED